Larotaxel (L) in combination with trastuzumab in patients with HER2 + metastatic breast cancer (MBC): Interim analysis of an open phase II label study

Autor:	Patrice Viens, Ahmad Awada, E. Lidbrink, H. Roche, D. Mery-Mignard, Corinne Veyret, Gilles Romieu, Véronique Diéras, Hervé Bonnefoi, Florence Dalenc
Rok vydání:	2008
Předmět:	Oncology Cancer Research medicine.medical_specialty Pathology business.industry medicine.disease Interim analysis Metastatic breast cancer Larotaxel Taxoid Trastuzumab Internal medicine medicine In patient business medicine.drug
Zdroj:	Journal of Clinical Oncology. 26:1070-1070
ISSN:	1527-7755 0732-183X
Popis:	1070 Background: Larotaxel (L), a semi-synthetic taxoid, has shown preclinical and clinical activity against taxane-resistant BC, and it presents the ability to cross the blood brain barrier. In HE...
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::003a89b8184edcbe3220e0138eb40dbe https://doi.org/10.1200/jco.2008.26.15_suppl.1070 Zobrazit plný text záznamu